This cell surface receptor which is involved in the recognition of iRBCs (infected red blood cells) [44] is also emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease (PD), and anxiety [45]. This evidence concerns the gene CD177 and central nervous system disorder.